- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
B-cell maturation antigen (BCMA) is a transmembrane protein member of the tumor necrosis factor (TNF) receptor superfamily, predominantly expressed on plasma cells, including malignant myeloma cells.1-3 Preclinical studies have shown that BCMA is essential for the survival of these cell types.1,3 Therefore, BCMA is a promising target protein in multiple myeloma through investigational therapies such as chimeric antigen receptor (CAR) T cell therapy, bispecific T-cell engagers, and antibody drug conjugates, among others.1,2